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Aims: This study sought to determine the usefulness of genetic testing to predict evolution in 
hypertrophic cardiomyopathy (HCM) and to assess the role of genetic testing in clinical 
practice. 
 
Methods and Results: Genetic results of 100 HCM patients tested for mutations in ≥10 HCM-
causing genes were evaluated. Patients were classified as with poor (Group A) or 
favourable(Group B) clinical course. Forty-five pathogenic mutations (PM) were identified in 28 
patients (56%) from Group A and in 23 (46%) from Group B (p=0.317).  Only 40 patients (40%) 
exhibited PM that had been previously reported and only 15 (15%) had PM reported in ≥10 
individuals. PM associated with poor prognosis were identified in just 5 patients from Group A 
(10%).  
 
Conclusion: Genetic findings are not useful to predict prognosis in most HCM patients. By 
contrast, real-world data reinforce the usefulness of genetic testing to provide genetic 
counselling and to enable cascade genetic screening. 
 
Word count: 150 






























HCM = hypertrophic cardiomyopathy 
HT = heart transplant 
ICD = implantable cardioverter defibrillator 
NGS = next generation sequencing 
PM = pathogenic mutation 
SCD = sudden cardiac death 
VUS = variant of uncertain significance 
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Clinical relevance of the manuscript 
Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease with a broad clinical 
spectrum related to its diverse genetic profile. Although genetic findings are not currently 
recommended to predict prognosis, very few studies have analysed this issue and controversy 
remains about the usefulness of genetic testing to predict disease progression.  
The current study provides comprehensive data to support the view that genetic findings are 
not useful to predict prognosis in HCM patients. Our results indicate that it is not appropriate 
to perform genetic testing in HCM patients to predict patients´ and relatives´ clinical course. By 
contrast, real-world data obtained in this study reinforces the usefulness of genetic testing to 




Hypertrophic cardiomyopathy (HCM) is the most frequent inherited cardiac disease [1,2]. 
Although most HCM patients have a good prognosis, a significant number suffer from life 
threatening complications, primarily sudden cardiac death (SCD) and end-stage heart failure 
[3,4]. 
The heterogeneous phenotypic expression of HCM has been related to its diverse genetic 
profile [5] and, to date, more than 1400 pathogenic mutations (PM) in >10 genes have been 
described to cause HCM [1,5]. 
The impact of genetics in the clinical course of HCM is controversial [6-8]. Although several 
studies suggest that some mutations associate with a poor clinical course [8-10], findings are 
inconsistent and large variations in clinical course are often seen in individuals harbouring the 
same genetic defect  [11–13].  
Current clinical guidelines advocate genetic testing in HCM to facilitate identification of 
relatives at risk of developing the disease, but not for establishing prognosis [14]. While the 
notion that genetic findings are not useful to predict prognosis in HCM is the predominant 
position among cardiomyopathy experts, it is important to state that very few studies have 
analysed this issue in depth and, consequently, there is little scientific evidence to support this 
accepted viewpoint. Furthermore, some studies have recently described several phenotype-
genotype associations for some mutations supporting the opposite viewpoint (that genetic 
findings allow prediction of clinical course) [9,10,16], and the American Heart 
Association/American College of Cardiology HCM guidelines include genetic findings as a 
modifier factor to predict SCD and guide implantable cardioverter defibrillator (ICD) 
implantation [17]. As such, controversy remains in the field. 
The impact of genetic testing in familial management and its ability to provide genetic 
counselling and reduce costs associated with periodic familial surveillance in real-world clinical 
practice has not been fully investigated. The aims of this study were twofold: first, to 
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determine if genetic testing is useful to predict prognosis in HCM patients with poor clinical 
course, and second, to analyse the usefulness of genetic testing in the real world.  
 
METHODS 
Patient Population  
We retrospectively identified 100 unrelated HCM patients followed at 2 inherited cardiac 
diseases units in Spain. Patients were selected after merging both units’ databases. For all 
patients, detailed clinical data at baseline (defined as their first presentation to participating 
units) and follow-up visits, as well as detailed genetic, family history, and echocardiographic 
data, were collected. Major adverse cardiac events were considered from birth to the last 
follow-up.  
Two groups of 50 individuals each were constructed by selecting the first 50 consecutive HCM 
index cases evaluated who had either “poor” or “favourable” clinical course and had 
undergone complete genetic evaluation (tested for ≥10 HCM-associated genes). Patients were 
genetically tested during the period 2008–2014. Patients were considered to have a poor 
clinical course if they had a SCD event, an appropriate ICD discharge and/or had required a 
heart transplant (HT) for end-stage heart failure. Patients with a “favourable clinical course” 
were those who had none of the above events during follow-up. The study was approved by 
the ethics committee of participant centres and conformed to the ethical guidelines of the 
Declaration of Helsinki. Informed written consent was obtained from all patients. 
 
Genetic evaluation 
Genetic testing was performed as part of the clinical service at both centres either by Sanger 
sequencing (29 cases) or by next generation sequencing (NGS) with a panel of genes 
associated with HCM (71 cases). The genetic testing technology used in each case depended 
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on local practice. Generally, all patients examined during the period 2008–2012 were tested by 
Sanger sequencing and NGS was used from 2013 onwards.  
Sanger sequencing included all coding exons and flanking intronic regions of the 10 most 
frequently mutated sarcomeric genes associated with HCM: MYH7, MYBPC3, TNNI3, TNNT2, 
TNNC1, TPM1, MYL2, MYL3, ACTC1 and LDB3. Based on clinical data, LAMP2, and PRKAG2 
were also examined in 4 individuals. DNA was sequenced on both strands. 
NGS analysis was undertaken at certified genetic testing laboratories using an inherited cardiac 
diseases gene panel including 56 genes associated with HCM (Supplemental material). Overall 
mean coverage of the samples was 1558 reads and 99.46% of the fragments had coverage >30. 
Sanger sequencing was used to confirm the genetic variants found and to evaluate fragments 
with low coverage in HCM-related genes. 
Genetic variants and allelic frequencies were scored based on dbSNP 
(www.ncbi.nlm.nih.gov/SNP), Exome Variant Server (EVS) (evs.gs.washington.edu), 1000 
Genomes (www.1000genomes.org), Ensembl (www.ensembl.org), Human Gene Mutation 
Database (HGMD® Professional) (http://www.hgmd.cf.ac.uk), and Exome Aggregation 
Consortium (ExAC) (exac.broadinstitute.org) databases. Only non-common variants (Minor 
Allele Frequency <0.01% in ExAC) were used in this study. In silico pathogenicity prediction of 
novel genetic variations was performed using Polyphen-2, PROVEAN and Mutation Taster. 
Sequence variants were classified as PM or variants of uncertain significance (VUS). Variants 
were considered PM if (i) they had been reported previously as disease-causing mutations 
associated with HCM in the literature or in online international databases such as ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/) and HGMD showing a minor allele frequency (MAF) 
<0.01% in the ExAC population; (ii) they were novel (not reported before as pathogenic in the 
literature) sequence variants in a previously HCM-associated gene, with a MAF <0.01% that 
predicted a premature truncation, frameshift or abnormal splicing of the protein; (iii) they 
were novel missense variants in a previously HCM-associated gene, with a MAF <0.01% that 
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cosegregated with the disease in the family; or (iv) that affects a highly conserved protein 
residue among species and with a predicted functional alteration in ≥2 of the 3 in silico 
software tools used, with a MAF <0.01% if familial genetic screening information is 
unavailable. Genetic variants were classified as VUS if they were novel missense variants in a 
previously HCM-associated gene, with unclear predicted in silico functional alteration and 
without evidence of familial cosegregation. Variants previously described in the literature as 
VUS were classified as such.  
Conservation of amino acid residues affected by genetic variants was determined using AlaMut 
(version 2.4.5; Interactive Biosoftware, Rouen, France) as previously reported [18].  
 
Review of literature 
After the identification of the PM in both groups, we reviewed all articles in which they had 
been reported (Supplemental material, no limitations to number of genes/patients applied) 
and the available information from PM carriers was extracted. By internal consensus, a PM 
was considered as “associated with poor prognosis” when it had been described in the 
literature in ≥10 individuals and when ≥20% of the reported gene carriers had had an adverse 
event (SCD, appropriate ICD discharge or HT). The last search was performed on March 10, 
2015. Additionally, to summarise the current information about genetic findings in different 
HCM populations, we undertook a search in PubMed for all studies published in the last 10 
years analysing ≥8 genes in ≥50 HCM individuals. The flow chart of the study selection process 
for this second literature review can be found in Supplemental material (Figure S1). 
 
Family screening 
First-degree relatives of probands with identified genetic variants were offered clinical 
(including ECG and echocardiography) and genetic evaluation. All relatives signed an informed 
consent. Cascade clinical and genetic screening was performed in additional relatives of first-
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degree relatives who were found to be carriers of PM. Genetic screening was not offered to 
relatives <16 years if they were asymptomatic and clinical evaluation was normal. 
 
Impact of genetic testing for reproductive/professional counselling  
We evaluated the clinical utility (reproductive, professional and sports counselling) derived 
from genetic testing and cascade genetic screening. For this purpose, we identified index 
patients and relatives who were ≤40 years old and had received reproductive counselling. 
Regarding the impact of genetic testing in the selection of a profession/job among genotype 
positive-phenotype negative and non-carriers, the cut-off age was set at 30 years. We 
considered that all individuals below this age might have benefited from knowing their genetic 
carrier status when electing a professional career. 
 
Impact of genetic testing in cost savings 
We reviewed the economic impact of genetic analysis, estimating the savings from cessation of 
monitoring of genotype-negative relatives. The cost of clinical monitoring in Spain was 
estimated as 303 Euro per each follow-up visit based on official healthcare costs lists (Table 6S. 
Supplementary material). Savings derived from the avoidance of lifetime clinical screenings 
were estimated for genotype-negative relatives according to their ages at the time of genetic 
testing and the expected total number of avoided evaluations until age 75 based on guidelines 
[14, 17]. No clinical screens were assumed for individuals older than 75 years.   
 
Statistical analysis 
Continuous variables are expressed as mean value ± standard deviation. Discrete variables are 
shown as percentages. Differences between means were compared using Student´s t-test and 
Mann−Whitney U test for normally distributed and non-normally distributed continuous data, 
respectively. Chi-squared with Yates’ correction and Fisher exact analyses were used to test for 
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associations between dichotomous variables. Probability values reported were two-sided and 
values <0.05 were considered statistically significant. All data were analysed using SPSS 




A total of 100 HCM patients were studied (52±15 years, 73% male). Fifty patients (52±16 years, 
68% male) were considered to have a “poor clinical course” [29 (58%) had a HT, 10 (20%) an 
aborted SCD and 15 (30%) an appropriate ICD discharge]. In this group, a total of 20 patients 
(40%) had family history of HCM and 14 (28%) had family history of unexplained SCD. Twenty-
two patients (44%) had impaired left ventricular ejection fraction and 30 (60%) had severe 
heart failure symptoms (NYHA III-IV) at the time of the adverse event. The mean maximal left 
ventricular wall thickness was 21±7 mm; 10 patients (20%) had left ventricular outflow tract 
obstruction and 3 patients (6%) had undergone surgical myectomy.  
The group of HCM patients with “favourable clinical course” comprised also 50 individuals 
(53±13 years, 78% male). Twenty-two patients (44%) had known family history of HCM and 17 
(34%) had family history of SCD. All except 3 patients had a normal ejection fraction and all 
were in NYHA class I-II. Nineteen patients (38%) presented left ventricular outflow tract 
obstruction and 5 (10%) had undergone myectomy. Nineteen patients (38%) had an ICD 
implanted for SCD primary prevention. 
Patients with poor clinical course were significantly younger at diagnosis (34±19 vs 43±15 
years; p=0.014) and presented more frequently left bundle branch block than patients with 
favourable clinical course (24% vs 6%; p=0.012). Table 1 summarises the phenotype of the 
study cohort.  
 
Genetic findings 
A total of 45 pathogenic mutations were identified in 51 HCM patients (51%). Among those 
with poor clinical course, 28 (56%) presented 24 PM in sarcomeric genes and 2 in LAMP2 
(Table 2S. Supplementary material). Genes most frequently mutated were MYBPC3 and MYH7 
(9 and 8 PM, respectively). A total of 17 PM (65%) had been previously reported as pathogenic, 
whereas 9 mutations (34%) were novel variants. Five patients (10%) carried multiple PM: 3 
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patients harboured a genetic defect in homozygosis (MYL2E22K, MYH7I144T and MYH7D778E) and 2 
patients showed combined heterozygosis (MYBPC3IVS23+1G>A with ACTC1L10M; and MYH7A797T with 
TNNI3R162Q). In patients with favourable clinical course, 22 PM were identified in 23 (46%) 
patients (Table 3S. Supplementary material). A total of 21 PM were found in sarcomeric genes 
and 1 in a non-sarcomeric gene (GLA). The most frequently affected gene was MYBPC3 (14 
PM). Five mutations (24%) were novel variants while 17 had previously been described as 
pathogenic. Only two patients (4%) harboured multiple PM, both in double heterozygosis 
(TPM1S215L and MYH7Q1215Hi; MYBPC3I1160N and GLAR301Q). 
The likelihood of identifying an HCM-associated mutation did not differ between the two 
groups (56% vs 46%; p=0.317); the gene distribution of PM in sarcomeric genes was also 
similar between both groups. Only 3 PM were identified in more than one individual and only 
2 were found in >3 unrelated patients: MYBPC3IVS23 dsG-A+1 and MYBPC3IVS22–1G>A (5 patients for 
each). The prevalence of complex genotypes did not differ between both groups (10% vs 4%; 
p=0.240).  
Overall, a higher frequency of family history of HCM was observed in genotype-positive 
patients versus genotype-negative patients (57% vs 33%; p=0.020), but no differences were 
observed between genotype-positive and genotype-negative individuals regarding family 
history of SCD (39% vs 23%; p=0.107) or age at HCM diagnosis (35.8 ± 18.9 vs. 41.9 ± 16 years, 
p= 0.087). 
 
Review of the literature 
A total of 14 of the 45 PM identified (31%) had not been previously reported and so no 
information was available in the literature. Information on the remaining 34 PM (17 in the 
poor and 17 in the favourable group) revealed that data from ≥10 genetic carriers were 
available only for 10 variants (8 present in the poor clinical course group and 4 in the 
favourable group) affecting 15 individuals included in the study (8 and 7 subjects from each 
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group). Adverse events were reported in ≥20% of carriers in 4 of these PM: MYBPC3IVS23dsG-A+1, 
MYH7D778E, MYH7R719W, and MYH7R719Q, implying that 4 out of the 46 PM identified (8%) could 
have been considered as associated with poor prognosis based on the published information 
(Tables 2 and 3). Conversely, 6 PM identified had been described in ≥10 genetic carriers in the 
literature with <20% of those carriers showing adverse events. These PM theoretically could 
have been considered as conferring "benign prognosis" based on the available information. 
Only 5 patients with poor clinical course had PM that could have predicted an adverse clinical 
course. Moreover, 3 patients (6%) of the poor clinical course group had PM thought to confer 
good prognosis (Figure 1). On the other hand, 3 patients with favourable clinical course had 
PM associated with poor prognosis and only 4 (8%) presented mutations that could have been 
considered as associated with benign prognosis (Figure 1). 
 
Impact of genetic testing 
A total of 119 relatives of HCM patients with PM were genetically studied (79 were relatives of 
patients with adverse clinical course and 40 of patients with favourable clinical course). 
Genetic study led to the identification of 57 PM carriers and 62 non-carriers. Non-carriers were 
released from future clinical surveillance, which was also not necessary in their offspring.  
Twenty-seven genetic carriers (45%) were found to have HCM while 30 genetic carriers were 
genotype positive-phenotype negative.  
As a result of cascade genetic testing, the definitive genetic status was known for 56 
individuals ≤40 years (14 index patients and 42 relatives). All of these individuals might benefit 
from knowing their genetic status in order to make informed reproductive decisions. 
Finally, 7 of the 30 genotype positive-phenotype negative relatives (23%) and 3 of the 60 non-
carriers (5%) were younger than 30 years and might therefore benefit from knowing their 
genetic status in selecting a professional career. 
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The estimated savings derived from the cessation of clinical screening of genotype-negative 
relatives was 83,022 Euro (697.66 Euro per relative). If we consider the cost of genetic 
screening for a single mutation (approximately 100 Euro) and compare it with the estimated 
avoided costs of serial clinical monitoring as recommended by Guidelines [14, 17], genetic 
















This study examines the usefulness of genetic findings to predict prognosis in HCM by studying 
two different cohorts of HCM patients: one with “poor clinical course” and one with 
“favourable clinical course”. After comprehensive genetic screening, our results are suggestive 
of a lack of usefulness of gene testing to predict prognosis in most HCM patients. In the 
present study, only a minority of HCM patients with a poor course presented PM that had 
been described previously in a substantial number of individuals and were known to be 
associated with a bad outcome. Furthermore, some HCM patients with poor clinical course 
presented PM that were associated with a benign clinical course and some HCM individuals 
with a favourable clinical course presented PM associated with poor prognosis. By contrast, 
real-world data obtained in this study reinforces the usefulness of genetic testing to provide 
genetic counselling and to enable familial evaluation. 
 
Genetic testing to predict prognosis in HCM 
The ability of genetic findings to predict prognosis in HCM has been a matter of debate for 
over 20 years [2, 5-7]. Initial attempts to demonstrate a relationship between a specific 
mutation and the resulting phenotype linked certain HCM-causing genes either with a 
favourable (MYBPC3) [19] or a negative (TNNT2) [8] outcome; however, later studies with a 
larger number of nonrelated patients showed that those gene-associations were inconsistent 
[11-13]. 
Although it has been demonstrated that HCM patients with a positive genetic test have a more 
severe disease phenotype than those with a negative genetic test [4], a recent meta-analysis 
has shown that it is not possible to establish an accurate gene-based genotype-phenotype 
relationship [20]. Along this line, our findings emphasise the genetic and clinical heterogeneity 
that characterises HCM with similar genetic background across both groups of patients 
studied. In fact, the overall prevalence and gene distribution of mutations has been shown to 
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be similar between different HCM populations (Table 4). In the present study, we also found 
that the distribution of affected genes was very similar between both studied groups; 
however, it should be noted that the number of patients with mutations in MYH7 was higher 
in the poor clinical course cohort. This trend is in accord with a higher prevalence of mutations 
in MYH7 in the paediatric population with HCM (Table 4) and with the younger presentation of 
MYH7 carriers among end-stage HCM patients reported by Biagini and coworkers [25]. Our 
findings and these suggest that MYH7 mutations could promote an earlier presentation of the 
disease compared with mutations in other genes.  
Previous studies have suggested that double or compound PM affect 3–5% of HCM individuals 
and are associated with a more severe clinical course [21-24]. Indeed, this was observed 
recently in a cohort of end-stage HCM patients where complex genotypes were twice more 
frequent than in the reference cohort [25]. Our results show a higher (although not statistically 
significant) frequency of complex genotypes in the poor prognosis group, which strengthens 
the hypothesis that the mutational load might have a deleterious effect; however, although 
the 10% prevalence of double PM in the adverse course group is considerable, the number of 
individuals with multiple PM remain a minority in this group, highlighting that clinical course of 
HCM is not primarily dependent on the presence of multiple PM. It is important to highlight 
the 3 patients with poor clinical course harbouring a genetic defect in homozygosis (no cases in 
the favourable clinical course group): two patients (MYL2E22K and MYH7D778E) had been 
reported previously [3, 26], whereas a patient with the homozygous mutation MYH7I144T was 
reported for the first time. Unfortunately, cosegregation of this mutation with the disease was 
not confirmed.   
Therefore, the severity of phenotypic expression in HCM seems to be modulated by multiple 
factors, including environmental and patients´ intrinsic factors [26,27]. Recent data suggest 
that factors that modulate disease phenotype such as hypertension might explain the extreme 
clinical heterogeneity of HCM among patients with the same mutation [26]. 
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Our findings do not question the usefulness of genetic testing to help in the identification of 
patients with phenocopies of sarcomeric HCM. Conditions including transthyretin familial 
amyloid cardiomyopathy, mitochondrial disorders and Danon’s and Fabry’s disease have a 
different underlying pathophysiology and a particular natural history, and so genetic results 
can help to predict prognosis and guide appropriate management in these individuals [5,7].  
 
Individual mutations are not useful to predict prognosis 
Our study shows that identifying a particular PM has little impact on predicting prognosis. This 
conclusion is based on 3 facts: (i) almost all PM were identified just in one individual (were not 
repeated); (ii) one third of PM identified were “novel” and the available information for most 
of the remaining PM was scarce; and (iii) a minority of PM could be classified as associated 
with “poor” or “benign” prognosis, with inconsistent behaviour in the patients of the two 
cohorts. 
To date, more than 1,400 mutations have been described in association with HCM and the 
majority are “private” mutations; consequently, it is extremely difficult to demonstrate 
genotype-phenotype correlations. Moreover, very few genotype-phenotype relationships have 
been shown to be reproducible because of the variable expression of the same or similar 
mutations [6,12,28]. We identified PM in two cohorts of patients with different prognosis, and 
extracted from the literature all available information about each one in order to predict 
clinical course. According to the information retrieved, five patients (10%) from the poor 
clinical course group carried a PM associated with poor prognosis, meaning that if it had been 
identified in advance it might have predicted the phenotypic expression. Therefore, in the best 
scenario, current genetic knowledge can be used to predict prognosis only in one of each 10 
HCM individuals that will develop serious adverse events. In the remaining individuals of our 
study with severe adverse outcomes, genetic study would have not helped in predicting the 
aggressive phenotype either because no PM would have been identified or because, even 
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though a mutation had been identified, the information currently available is insufficient to 
test its clinical significance. In accordance with this lack of usefulness, three patients (6%) from 
the poor clinical course group carried PM associated with a good clinical profile and three 
patients without clinical events harboured PM theoretically associated with poor prognosis. 
Supporting these findings, 14 patients with poor clinical course and 17 with favourable clinical 
course had a family history of SCD, underscoring the variation in clinical course between 
relatives hosting the same PM.  
One of the limitations of this study is its relatively small sample size. However, it is difficult to 
recruit a large number of nonrelated patients who share some specific clinical features. In the 
present study, we genotyped 50 unrelated patients with a poor clinical course and compared 
their genetic background with that from a group of individuals with a good clinical profile. The 
principal objective of this study was to provide data about the usefulness of genetic study 
results in predicting patient’s clinical course. The available literature of the genetic variants 
found in both groups provided useful data to correctly predict the clinical evolution of HCM 
patients in just 9 (9%) individuals (5 from the “poor” and 4 from the “favourable” group).  
Despite the limited sample size of the study, these results support the view that the 
identification of a causal mutation is currently not clinically useful in predicting prognosis in 
HCM.  
 
Family screening and implications for relatives 
Current guidelines recommend genetic testing in HCM patients to facilitate identification of 
relatives at risk of developing the disease and to provide genetic counselling [14,17]. Genotype 
determination can be used to precisely identify relatives at risk for developing disease at an 
early stage and focus longitudinal follow-up or, conversely, to discharge relatives who have not 
inherited the PM and are not at risk for disease development. Although this gene-based 
diagnostic strategy in families has proven to be cost-effective in theoretical economic models 
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[29], its clinical impact for reproductive and sports/professional career counselling has not 
been evaluated. 
In this study with real-world patients, family screening revealed 57 mutation carriers (27 with 
HCM) and 62 non-carriers. Relatives not carrying a PM and their offspring were reassured and 
did not require clinical evaluation or lifestyle restrictions. The recommended periodic 
monitoring for relatives of HCM patients in whom the genetic status is unknown includes 
medical consultation, electrocardiogram and echocardiography [14,15]. This translates 
approximately to a cost of 303 Euro per visit in Spain [30, 31]. Over time, the serial clinical 
follow-up of relatives would represent a considerable cost to the health system. Current NGS 
genetic testing for HCM in an index patient is commercially available for less than 1000 Euro, 
and testing of relatives for individual mutations costs less than 100 Euro. These costs will 
continue to decrease in the coming years, but even with current costs the estimated savings 
derived from cessation of follow-ups are relevant.  
In our study, we also estimated the benefit derived from offering reproductive, professional 
and sports counselling. Forty-two relatives ≤40 years old knew their genetic status and could 
receive reproductive advice. Relatives found to be carriers of a PM were informed about 
reproductive methods to prevent PM transmission and those with a negative genotype were 
informed that their descendants would not have the disease. 
Clinical practice guidelines recommend patients with a PM without phenotype to participate in 
recreational sport activities, avoid competitive sports, and choose the activity on an individual 
basis [14]. However, recommendations for professional activities are not established. It seems 
reasonable to advise young people with a disease-related mutation on these issues. Ten 
relatives ≤30 years old underwent genetic testing and benefited from professional and sports 
counselling in our study. 
A recent study from the Mayo clinic has shown that only a minority of HCM patients at this 
institution chose to be genetically tested [32]. Although the reasons for declining or accepting 
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genetic testing are complex and are dependent on individual patient characteristics and 
circumstances, we believe that the benefits found in our work could be used to support 
genetic testing in HCM patients. 
 
Conclusions 
Our results indicate that it is currently not feasible to predict a patient´s clinical course based 
solely on the genetic defect identified. The clinical value of genetic testing is currently limited 
to familial genetic counselling, in particular for relatives who are considering predictive genetic 
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Table 1.  Phenotype of the entire HCM cohort (n=100) 
 
Table 2. Pathogenic mutations found in HCM patients with “poor clinical course” with the 
prognostic information available in the literature 
 
Table 3. Mutations found in HCM patients with “favourable clinical course” with the 
prognostic information available in the literature 
 





Figure 1. Pie charts reflecting predictive information based on genetic findings in 100 HCM 
index cases with poor (A) or favourable (B) clinical course. 
Mutations without information are those described in <10 individuals previously. 
 
 
 
 
 
